FGFR1 and neoplasm: However, residual tumor cells survived from cabozantinib treatment due to vascular heterogeneity represents a mechanism of cabozantinib resistance, and the initiation of the expression of FGFR1 in tumor cells is another potential mechanism of acquired resistance to cabozantinib (87).